Dacarbazine

Evidence Level: L4

Predicted Indications: 10

Dacarbazine
Dacarbazine: From Hodgkin Lymphoma and Metastatic Melanoma to Upper Aerodigestive Tract Neoplasm

## Pharmacist Assessment Report

Dacarbazine: From Hodgkin Lymphoma and Metastatic Melanoma to Upper Aerodigestive Tract Neoplasm

One-Sentence Summary

Dacarbazine is a DNA-alkylating chemotherapy drug originally used for Hodgkin lymphoma and metastatic melanoma. The TxGNN model predicts it may be effective for upper aerodigestive tract neoplasm, but no clinical trials and only indirect literature (about 20 publications on related tumours) currently support this prediction.

Quick Overview

Item	Content
Original Indication	Hodgkin lymphoma and metastatic melanoma (the Singapore licence records contain no indication text)
Predicted New Indication	Upper aerodigestive tract neoplasm
TxGNN Prediction Score	99.26%
Evidence Level	L4
Singapore Market Status	✓ Marketed
Number of Registrations	2
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, dacarbazine is a DNA-alkylating agent. It is a methylating prodrug activated by hepatic metabolism, and its efficacy in melanoma and Hodgkin lymphoma (as part of the ABVD regimen) is established.

The retrieved literature touches the head and neck region only indirectly. It covers mucosal melanoma, Hodgkin lymphoma at head and neck sites, paraganglioma, and medullary thyroid carcinoma. These are dacarbazine-sensitive tumour types that can occur in that region. No study tests dacarbazine in squamous cell carcinoma of the upper aerodigestive tract, which is the typical meaning of this predicted indication. The high TxGNN score is therefore not backed by direct clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered for this predicted indication.

(For reference, two early-phase dacarbazine combination trials were linked to the broader "head and neck cancer" prediction, but both enrolled melanoma, sarcoma or medullary thyroid carcinoma patients, not upper aerodigestive tract cancer.)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41481311	2026	RCT	JAMA Oncology	Phase 3 MELATORCH trial of toripalimab vs dacarbazine as first-line therapy in acral melanoma (dacarbazine is the comparator)
7826911	1994	Cohort	Annals of Oncology	Dacarbazine plus 5-fluorouracil in advanced medullary thyroid cancer
20564093	2010	Cohort	Cancer	Characteristics and outcomes of Hodgkin lymphoma at extranodal and nodal head and neck sites
34654328	2024	Cohort	Ear, Nose & Throat Journal	Six patients with head and neck malignant paraganglioma: clinical features and treatment options
31621203	2019	Prospective observational	Cancer Medicine	Carbon-ion radiotherapy plus dacarbazine, nimustine and vincristine (DAV) for head and neck mucosal melanoma (n=21)
11815960	2002	Preclinical	Cancer	Dacarbazine combined with radioimmunotherapy in medullary thyroid carcinoma xenografts in mice
20627492	2010	Review	Clinical Oncology	Overview of medullary thyroid carcinoma
12845209	2003	Case report	Onkologie	Mucosal metastases of malignant melanoma, including the palatine tonsil
29443738	2018	Case report	Medicine	Hodgkin lymphoma of the tonsil misdiagnosed as tonsillar carcinoma
12113649	2002	Review	American Journal of Clinical Dermatology	Current concepts in melanoma management

Singapore Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN12499P	DAC Powder for Injection 200 mg/vial	Injection, powder, for solution	Not stated in the licence record
SIN06424P	DBL Dacarbazine for Injection 200 mg	Injection, powder, for solution	Not stated in the licence record

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (DNA-alkylating agent)
Myelosuppression Risk	High (the knowledge graph links dacarbazine to leukopenia, thrombocytopenia and anaemia as risk conditions)
Emetogenicity Classification	High
Monitoring Items	Complete blood count with differential, liver function, renal function
Handling Protection	Must follow cytotoxic drug handling regulations

Please also refer to the package insert warnings and precautions.

Safety Considerations

Conditions flagged in the knowledge graph (not label text): kidney disease, liver disease, gallbladder disease, pyoureter, thrombocytopenia, anaemia (including macrocytic anaemia), leukopenia, hepatic vein thrombosis, and Budd-Chiari syndrome. Liver-related items are consistent with the known risk of hepatic vein thrombosis and hepatocellular necrosis with dacarbazine, and the haematological items with its myelosuppression.
Drug Interactions: 100 interactions were identified. The main ones with a graded severity are naltrexone (Moderate) and levofloxacin (Minor). Many others, including pantoprazole, omeprazole, morphine, metformin, prednisone, simvastatin, ondansetron and aprepitant, have no severity grade assigned.

Please refer to the package insert for the full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by model scoring and indirect literature on other tumour types occurring in the head and neck region. No trial tests dacarbazine in upper aerodigestive tract cancer, and the drug's substantial haematological, hepatic and emetic toxicity is hard to justify without efficacy evidence.

To proceed, the following is needed:

Clarification of which tumour types the predicted indication covers (squamous carcinoma versus dacarbazine-sensitive histologies such as mucosal melanoma)
Direct clinical or preclinical efficacy data in the target population
Detailed mechanism of action data
Package insert warnings and contraindications from the HSA website, and the approved indication text for both Singapore licences
A comparison against current standard therapies for the target tumour types
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.